Quoin Pharmaceuticals Ltd. (QNRX) Current Ratio
- Current ratio · latest quarter: Value 1.76×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.76× | Current assets / current liabilities. $11.64M ÷ $6.61M ≈ 1.76× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 11.64M USD | Assets, Current |
| Current obligations | 6.61M USD | Liabilities, Current |
| Cash and equivalents | 3.85M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.11M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.64M | $6.61M | $3.85M | (m) | (m) | (m) | $3.11M | (m) | 1.76× |
| 2026-03-31 | $15.33M | $5.35M | $3.12M | (m) | (m) | (m) | $1.78M | (m) | 2.87× |
| 2025-12-31 | $20.01M | $5.55M | $3.82M | (m) | (m) | (m) | $1.26M | (m) | 3.61× |
| 2025-09-30 | $6.02M | $5.76M | $1.83M | (m) | (m) | (m) | $1.86M | (m) | 1.04× |
| 2025-06-30 | $8.48M | $4.34M | $1.67M | (m) | (m) | (m) | $873.68K | (m) | 1.95× |
| 2025-03-31 | $12.50M | $4.86M | $3.82M | (m) | (m) | (m) | $644.06K | (m) | 2.57× |
| 2024-12-31 | $14.93M | $4.18M | $3.62M | (m) | (m) | (m) | $905.70K | (m) | 3.57× |
| 2024-09-30 | $10.50M | $3.47M | $3.12M | (m) | (m) | (m) | $222.64K | (m) | 3.02× |
| 2024-06-30 | $13.22M | $3.95M | $2.85M | (m) | (m) | (m) | $819.67K | (m) | 3.35× |
| 2024-03-31 | $15.26M | $4.22M | $1.83M | (m) | (m) | (m) | $358.51K | (m) | 3.61× |
| 2023-12-31 | $11.29M | $3.58M | $2.40M | (m) | (m) | (m) | $526.52K | (m) | 3.15× |
| 2023-09-30 | $14.14M | $4.58M | $3.16M | (m) | (m) | (m) | $239.98K | (m) | 3.09× |
| 2023-06-30 | $15.67M | $4.41M | $4.76M | (m) | (m) | (m) | $707.93K | (m) | 3.55× |
| 2023-03-31 | $17.39M | $4.16M | $3.37M | (m) | (m) | (m) | $281.09K | (m) | 4.18× |
| 2022-12-31 | $13.37M | $3.53M | $2.86M | (m) | (m) | (m) | $605.60K | (m) | 3.79× |
| 2022-09-30 | $15.66M | $3.60M | $5.25M | (m) | (m) | (m) | $280.70K | (m) | 4.35× |
| 2022-06-30 | $3.51M | $3.67M | $2.69M | (m) | (m) | (m) | $768.67K | (m) | 0.96× |
| 2021-12-31 | $8.20M | $4.58M | $7.48M | (m) | (m) | (m) | $923.24K | (m) | 1.79× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |